Oct. 30 - How the pandemic fueled one of 2020's top biotech IPOs | Safety concerns raise questions for Regeneron's COVID-19 drug

Safety concerns lead Regeneron to halt testing of COVID-19 drug in some patients; Record numbers of biotechs are going public. Here's how they're performing.; Axovant shares sink on manufacturing delay for Parkinson's gene therapy View online | Signup | Forward

Daily Dive Oct.​ 30,​ 2020 | Today's news and insights for biopharma leaders   BROUGHT TO YOU BY — PQE Group Innovate your quality, with PQE Group Choose our smart solutions to enhance data integrity. Request demo.   Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs The Boston startup's initial public offering is the fourth-largest in biotech this year, according to data compiled by BioPharma Dive. Safety concerns lead Regeneron to halt testing of COVID-19 drug in some patients A study monitoring board flagged a "potential safety signal" in some hospitalized COVID-19 patients who require breathing support, telling the biotech to modify its study protocol. UPDATED Record numbers of biotechs are going public. Here's how they're performing. Three biotechs raised $456 million this week, headlined by Atea's $300 million offering. See how they compare to the past three years of IPOs.   Sponsored Content by Millipore Sigma Optimize your biologic's analytical program for greater risk reduction In this ebook, our experts share critical success factors for your analytical program and describe strategies and their impact on speed to clinic, speed to market and risk. Read ebook. Axovant shares sink on manufacturing delay for Parkinson's gene therapy A longer-than-expected timeline for developing a new manufacturing process means a key study for Axovant's top gene therapy likely won't begin until 2022. Read more news Featured Resources FROM: WCG Getting medicines and care with the speed we need while keeping patients safe during COVID-19 It's All About the Trust: Authentic Community Engagement Key to Diverse Trial Enrollment Advocating for Patients in a Time of COVID-19 There is Value to Patients When Independent Sites Offer Clinical Trials From Our Library Trendline Trends and Developments in Real-World Evidence View all resources What We're Reading Associated Press Lab tests show risks of using CRISPR gene editing on embryos Axios States beg for Warp Speed billions to distribute COVID-19 vaccines AstraZeneca AstraZeneca sells commercial rights to two drugs in $400 million deal Bloomberg How Hims Built An Online Prescription Drug Empire On Outdated Oversight Suggest a story we should read Upcoming Events Transforming the Pharma Supply Chain with Blockchain Nov. 11, 2020 - Nov. 11, 2020 | Webinar 2pm ET Optimizing IRT Design and Management to Future Proof Your Trial Nov. 17, 2020 - Nov. 17, 2020 | Webinar 11am ET Company Announcements Press releases from companies in your industry. RCPE awarded two FDA contracts for next-generation pharma technology Press release from RCPE - Research Center Pharmaceutical Engineering GmbH Lumis International GmbH spins off its consulting business to Lumis Life Science Consulting GmbH Press release from Lumis International GmbH Post a press release Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip